DSIP

Batch #119258Batch # 119258
Report #11200Report # 11200
Tested at99.84% PurityTested at 99.84% Purity
Size: 5mg
Money Back Guarantee Money Back Guarantee
Satisfaction Guarantee Satisfaction Guarantee
Easy Returns Easy Returns
Secure Ordering Secure Ordering
2-Day Shipping 2-Day Shipping
Third Party Tested Third Party Tested
Batch & Lot Tracking Batch & Lot Tracking

RESEARCH USE ONLY
These compounds are NOT intended for human consumption, clinical use, or veterinary applications. We are not affiliated with any pharmaceutical companies or their commercial medications. By placing an order, you certify these materials will be used exclusively for in vitro testing and laboratory experimentation only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic.

About DSIP

DSIP is a naturally occurring neuropeptide fragment studied in basic research settings related to cellular signaling and peptide biochemistry. This material is intended strictly for laboratory research (e.g., in vitro assays, method development). No medical, diagnostic, or veterinary applications.

Product Specifications

DSIP Lyophilized Powder in 3ml vial.

Application

Research peptide with potential in sleep regulation and neuroprotective studies

Appearance

Solid, white powder in 3mL glass ampule

Chemical Formula

C35H48N10O15

PubChem CID

3623358

CAS Number

62568-57-4

Molecular Weight

848.81 g/mol

Synonyms

DSIP, Delta Sleep-Inducing Peptide

Storage

Store at ≤6°C, sealed, away from heat, light, and moisture.

1. Overview   

Delta Sleep-Inducing Peptide or DSIP is a natural brain peptide first discovered in 1977. It has been well studied for the purpose of rejuvenating sleep, normalizing sleep-wake cycles, and overall daytime functioning in people with chronic insomnia. DSIP seems to normalize sleep patterns without the risk of sedation or dependence, which makes it a promising compound for supporting restorative sleep-wake cycles.

 

2. Key Findings from Human Trials  

In an open study, ten DSIP injections were given to seven subjects with severe insomnia. Sleep normalized in six, with normalization ranging from three to seven months following treatment. The great majority also reported feeling more energetic and alert during the day with no side effects. Only one patient with a history of drug use responded more slowly to treatment.

A second double-blind trial studied DSIP in fourteen individuals with chronic insomnia. They got DSIP injections for seven consecutive nights. As a result, they slept better and felt more awake during the day. The benefits persisted even after the treatment ended, and participants’ sleep patterns resembled those of healthy sleepers.

In a small clinical study, six chronic insomniacs were given a single i.v. dose of DSIP (25 nmol/kg) increased total sleep and decreased nighttime interruptions. Participants slept slightly longer in REM sleep, and there were no signs of morning drowsiness or side effects.

A five-night placebo-controlled trial with sixteen patients found that DSIP helped people fall asleep faster and sleep more efficiently than the placebo group. Some also felt less tired the next day, but the overall improvement was mild. Researchers suggested DSIP may help with moderate insomnia, though more research is needed to confirm long-term effects.

 

3. Safety and Tolerability  

No major side effects were reported in any of the human trials with DSIP. There was also no morning drowsiness, craving and withdrawal effects. The findings also suggest DSIP exhibits an excellent safety record even when administered for long periods of days. Nevertheless, further clinical studies are needed to establish its ideal dosing and long-term safety as well as potential therapeutic uses.

 

References

  1. Brandenberger G, et al. “Effects of delta sleep-inducing peptide (DSIP) on sleep of chronic insomniacs.” Sleep, 1985.

  2. Kovalzon V.M. “Sleep-promoting effects of DSIP injections in patients with insomnia.” Neurobiology Journal, 1980.

  3. Wiegand M., et al. “Delta sleep-inducing peptide improves sleep and daytime function in chronic insomnia.” Psychopharmacology, 1991.


 

You ask,
we answer.